Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan 25:2023:4655109.
doi: 10.1155/2023/4655109. eCollection 2023.

Shuangdan Mingmu Capsule for Diabetic Retinopathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Jiaan Du  1 , Yingqi Mao  1 , Youhua Xu  1   2 , Kai Qu  3 , Aiwei Han  1 , Qibiao Wu  1   2   4   5 , Lili Yu  1   2
Affiliations
Review

Shuangdan Mingmu Capsule for Diabetic Retinopathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Jiaan Du et al. Evid Based Complement Alternat Med. .

Abstract

Objective: To systematically evaluate the efficacy and safety of the Shuangdan Mingmu capsule in the treatment of diabetic retinopathy (DR).

Methods: Common Chinese and English databases, including PubMed, Medline, Embase, VIP, Wanfang, and the Chinese National Knowledge Infrastructure (CNKI), were searched from their inception to May 31, 2022. According to the Cochrane Handbook, two reviewers independently evaluated and collected data on the included studies. Meta-analysis was performed by RevMan software 5.4.

Results: Seven trials with a total of 835 patients were included. The clinical effectiveness rate was defined as the primary outcome, and the TCM symptom score, Chinese-Version Low Vision Quality of Life Questionnaire (CLVQOL) scores, macular thickness, hemorrhagic spot area, vascular endothelial growth factor levels, platelet-derived growth factor levels, and the incidence of adverse effects were the secondary outcome. The results of the meta-analysis showed that, compared with conventional medical treatment alone, the Shuangdan Mingmu capsule combined with conventional treatment could significantly improve the clinical effectiveness rate of treating DR (OR = 4.07, 95% CI (2.10, 7.89), p < 0.0001), and reduce the incidence of adverse reactions in DR patients (OR = 0.47, 95% CI (0.26, 0.86), p=0.01). In addition, other results showed that TCM symptom score(OR = -3.47, 95% CI (-3.84, -3.10), p < 0.00001); CLVQOL scores (OR = 23.93, 95% CI (21.37, 26.49), p < 0.00001); macular thickness (OR = -47.34, 95% CI (-50.67, 44.00), p < 0.00001); hemorrhagic spot area (OR = -0.91, 95% CI (-1.01, -0.81), p < 0.00001); vascular endothelial growth factor levels (OR = -45.76, 95% CI (-49.74, 41.79), p < 0.00001); platelet-derived growth factor levels (OR = -1.73, 95% CI (-2.15, -1.31), p < 0.00001).

Conclusion: Compared with conventional treatment alone, the Shuangdan Mingmu capsule combined with conventional treatment is more effective and safer in the treatment of diabetic retinopathy. However, due to the limitations of the included studies, more high-quality studies are still needed to further assess the efficacy and safety of the Shuangdan Mingmu capsule in the treatment of diabetic retinopathy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
A systematic review and meta-analysis diagram of the search.
Figure 2
Figure 2
Risk of bias graph.
Figure 3
Figure 3
Risk of bias summary.
Figure 4
Figure 4
Clinical effective rate.
Figure 5
Figure 5
TCM symptom score.
Figure 6
Figure 6
CLVQOL scores.
Figure 7
Figure 7
Macular thickness.
Figure 8
Figure 8
Hemorrhagic spot area.
Figure 9
Figure 9
Vascular endothelial growth factor levels.
Figure 10
Figure 10
Platelet-derived growth factor levels.
Figure 11
Figure 11
Adverse reactions.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Yi S., Zhou Q. Interpretation of clinical guidelines for diabetic retinopathy of the American Academy ofOphthalmology 2018. Rec Adv Ophthalmol . 2019;39(6):501–506.
    1. Laddha Ap, Kulkarni Ya. Tannins and vascular complications of Diabetes: an update. Phytomedicine . 2019;56:229–245. doi: 10.1016/j.phymed.2018.10.026. - DOI - PubMed
    1. Klein B. E. K. Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiology . 2007;14(4):179–183. doi: 10.1080/09286580701396720. - DOI - PubMed
    1. Chinese Diabetes Society Retinopathy Group. Expert consensus on prevention and treatment of diabetic retinopathy. Chin J Diabetes Mellitus . 2018;10(4):241–247.
    1. Qin Y., Fang Li, Tu L., et al. Multicentric clinical study of Shuangdan Mingmu capsule on diabetic retinopathy. Journal of TCM Univ. of Hunan . 2010;30(1):46–51.

LinkOut - more resources